Navigation Links
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date:4/30/2008

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following investor conferences in May.

Deutsche Bank 33rd Annual Health Care Conference

InterContinental Boston

Tuesday, May 6, 2008

8:50 a.m. ET

Bank of America Health Care Conference

Four Seasons Hotel, Las Vegas

Tuesday, May 13, 2008

11:00 a.m. ET

Rodman & Renshaw 5th Annual Global Health Care Conference

Le Meridien Beach Plaza Hotel, Monte Carlo

Monday, May 19, 2008

9:30 a.m. ET

The presentations will be audio webcast live and available for replay from Dendreon's website, http://www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Announces Closing of Registered Direct Offering
2. Dendreon Announces $47 Million Registered Direct Offering
3. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
4. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
5. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
6. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
9. Dendreon Reports Third Quarter 2007 Financial Results
10. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
11. Dendreon Secures $130 Million Committed Equity Financing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... financial planning for corporate executives and entrepreneurs, held The Future of San Diego Life ... in the San Diego life science community attended the event with speakers Dr. Rich ...
(Date:5/23/2016)... ... 23, 2016 , ... PrecisionAg® Media has released its latest ... The paper outlines the key trends that are creating both opportunities and challenges ... lot of highs and lows as the precision agriculture market has grown and ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):